To determine whether miR-143 is sensitive to Taxol treatment in cervical cancer, the changes in the expression of miR-143 and its target protein bcl-2 before and after NACT were detected in 24 patients who were treated effectively. The gene discussed is BCL2; the disease is cervical carcinoma.